Healthspan becomes a bigger part of the healthy ageing debate

Genflow Biosciences Plc

Living longer is only part of the ageing story. Increasingly, the focus is moving towards how many of those years are spent in good health. Lifespan refers to the total number of years a person lives. Healthspan refers to the years spent in relatively good physical and mental health, with fewer serious limitations caused by disease, pain or loss of independence.

Longer life does not always mean healthier life. People may live for many years while managing chronic conditions that affect mobility, independence and overall quality of life. As a result, healthy ageing is becoming less about extending life alone and more about extending the period of life spent in good health.

This shift has wider relevance as ageing populations increase demand for healthcare, prevention, monitoring and long-term support. It also places more attention on the factors that can influence health over time.

Genetics remains part of the picture, but lifestyle and environment can also play an important role. Regular physical activity, a balanced diet, good sleep, avoiding tobacco and maintaining social connections can all support healthier ageing. Preventive healthcare, including routine checks and appropriate screening, can also help identify potential problems earlier.

Managing common health risks is another important part of maintaining healthspan. Blood pressure, cholesterol, blood sugar and body weight can influence the risk of developing conditions that become more common with age. Addressing these areas earlier may help reduce the impact of disease later in life.

Physical strength and mobility are particularly important. Maintaining muscle, balance and cardiovascular fitness can support independence and reduce the likelihood that everyday activities become more difficult with age.

Mental and social wellbeing also contribute to healthy ageing. Staying connected with other people, remaining mentally active and managing stress can support overall health alongside more traditional medical measures.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Healthspan becomes a bigger part of the healthy ageing debate

Healthspan is becoming a key part of the longevity discussion as attention shifts from simply living longer to staying healthier for more of those years.

Genflow nears key data readout for SIRT6 gene therapy platform

Genflow is nearing a key data point as it combines animal study results, specialist RNA delivery support and broader patent protection.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

Genflow Biosciences advances SIRT6 patent portfolio in US and Europe

Genflow Biosciences has reported progress on its SIRT6 patent families, including a published US application and Track One examination.

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study.

Genflow Biosciences advances a focused gene therapy pipeline for healthy ageing

Genflow Biosciences is building a focused SIRT6 gene therapy pipeline across human health, veterinary medicine and skin-related applications.

Search